Berberine
Berberine is a bitter yellow alkaloid from goldenseal, barberry, Oregon grape, and Chinese goldthread. In trials it lowers fasting glucose, A1c, and LDL cholesterol through mechanisms that partly overlap with metformin's, and very little of an oral dose reaches the blood. Social media calls it "nature's Ozempic." It is not.
This page contains affiliate links. Titrate earns a small commission when you purchase through them, at no cost to you. This does not affect our recommendations.
What It Does
Berberine inhibits complex I of the mitochondrial respiratory chain. The resulting rise in AMP relative to ATP activates AMPK, the cell's energy sensor (Lee 2006), which is also the pathway metformin acts on. The liver releases less glucose and muscle takes up more. Separately, berberine stabilizes the messenger RNA for the hepatic LDL receptor, raising receptor numbers by a route distinct from statins (Kong 2004). Because so little is absorbed, part of its effect probably begins in the gut, through the microbiome and bile acid metabolism.
The glucose data are consistent, if not large. In a small trial in newly diagnosed type 2 diabetes, 500 mg three times daily for three months lowered A1c from about 9.5% to 7.5%, similar to metformin in the same study (Yin 2008). A 2015 meta-analysis of 27 trials found that berberine with lifestyle change lowered glucose, A1c, LDL, and triglycerides more than lifestyle change alone, and added to the effect of oral diabetes drugs (Lan 2015). Most trials were Chinese, short, and of uneven quality.
The weight story is where the marketing outruns the data. Semaglutide and tirzepatide act on GLP-1 receptors in the brain and gut to cut appetite, producing double-digit percentage weight loss. Berberine has no such action. Obese adults taking 500 mg three times daily for 12 weeks lost about 5 pounds (Hu 2012). The real case for berberine is glucose and lipids.
Berberine inhibits CYP3A4, CYP2D6, and CYP2C9 after two weeks of use (Guo 2012), so it can raise blood levels of drugs cleared by those enzymes. It displaces bilirubin from albumin, which makes it unsafe in pregnancy, while breastfeeding, and in newborns. Long-term metformin use lowers vitamin B12; whether berberine does the same has not been studied in humans, and for long-term users a periodic B12 level is a cheap precaution.
Forms and Bioavailability
Absorption ratings are broad tiers. Head-to-head human trials rarely support a finer ranking among well-absorbed forms.
| Form | Absorption | Typical dose | Cost | Labels |
|---|---|---|---|---|
| Berberine HClberberine hydrochloride | LowPoorly absorbed and pumped back into the gut lumen by P-glycoprotein; oral bioavailability was below 1% in rats. Part of its metabolic effect may begin in the gut. | 500 mg 2-3 times daily with meals | Low | 230 |
| DihydroberberineDHB, GlucoVantage | VariableA reduced form converted back to berberine after absorption. A five-person crossover pilot found higher plasma berberine from 100-200 mg than from 500 mg berberine HCl. | 100-200 mg 1-2 times daily | High | |
| Berberine, Lipid-Based Deliveryliposomal berberine, berberine phytosome | VariablePhospholipid, micellar, or liposomal carriers meant to raise absorption and sidestep P-glycoprotein efflux. Published human pharmacokinetic data are limited and specific to each product. | Per product; often 200-550 mg daily | High | 5 |
Labels column: number of labels named as berberine products that list this form. A product can list more than one form, and some labels do not state a form at all.
Absorption is the central problem. In rats, oral bioavailability of berberine was below 1% (Chen 2011): it is poorly soluble, pumped back into the gut by P-glycoprotein, and heavily metabolized on first pass. Two strategies try to fix this. Dihydroberberine is a reduced form that converts back to berberine after absorption; a five-person pilot found higher plasma berberine from 100-200 mg than from 500 mg of berberine HCl (Moon 2021). Lipid-based systems (phytosome, liposomal, and micellar products) wrap berberine in phospholipids or emulsifiers. Each delivery system has its own limited data, and results do not transfer from one brand to another.
Typical Dosing
Glucose and lipid trials mostly used 500 mg two or three times a day with meals (1,000-1,500 mg daily) for 8-12 weeks or longer.
What to Look For
The panel should name the form and the milligrams of berberine per capsule. Some products list a Berberis aristata extract with a berberine percentage; multiply to get the actual dose. Standard berberine HCl is taken with meals, 500 mg two or three times daily. Start with one dose a day and add the others over a week or two to limit cramping and constipation.
In my practice, the liposomal form (Bioclinic Naturals Berberine Lipomicel Matrix) has produced consistent reductions in fasting glucose, A1c, and ApoB that I did not see with powdered formulations. Bioavailability appears to be the differentiator.
Anyone taking insulin, a sulfonylurea, or another glucose-lowering drug should monitor glucose closely after starting, since the effects add. Check every medication for CYP3A4, CYP2D6, or CYP2C9 metabolism with a pharmacist, and do not use berberine in pregnancy or while breastfeeding.
Red flags: "nature's Ozempic" or "GLP-1" marketing, weight-loss blends that pair berberine with stimulants, and products that do not state milligrams of berberine. Green flags: a named form, milligrams per capsule, and third-party testing.
Berberine, Lipid-Based Delivery
Absorption is the limiting factor for berberine, and lipid delivery addresses it directly. Data are product-specific, so choose a delivery system with a track record.
What to look for: Bioclinic Naturals Berberine Lipomicel Matrix is the product behind the clinical observation above. Milligrams of berberine per softgel stated.
Find on iHerb Affiliate linkBerberine HCl
The form in nearly every published trial and the least expensive. Expect GI side effects at full dose.
What to look for: Berberine HCl, 500 mg per capsule, taken with meals. USP, NSF, or similar testing.
Find on iHerb Affiliate linkDihydroberberine
Better absorbed in a tiny pilot, with no outcome trials. An option when berberine HCl is not tolerated.
What to look for: Dihydroberberine (GlucoVantage) at 100-200 mg per dose.
Find on iHerb Affiliate linkProducts on Titrate
710 of the 214,745 labels in the NIH Dietary Supplement Label Database list berberine as an active ingredient (409 on market). 325 are sold as berberine products by name.
Top on-market labels, ranked by label completeness and simplicity:
- Berberine, Turmeric & BioPerine
- Berberine
- Berberine with InSea2
- Berberine, Turmeric & BioPerine
- Berberine
Berberine does not have its own search category yet. Each product above links to its full label in the NIH database.
Related Tools
References
National Center for Complementary and Integrative Health. Goldenseal.
Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10(12):1344-1351.
Lee YS, Kim WS, Kim KH, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006;55(8):2256-2264.
Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57(5):712-717.
Chen W, Miao YQ, Fan DJ, et al. Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats. AAPS PharmSciTech. 2011;12(2):705-711.
Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 2012;68(2):213-217.
Hu Y, Ehli EA, Kittelsrud J, et al. Lipid-lowering effect of berberine in human subjects and rats. Phytomedicine. 2012;19(10):861-867.
Lan J, Zhao Y, Dong F, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015;161:69-81.
Moon JM, Ratliff KM, Hagele AM, et al. Absorption kinetics of berberine and dihydroberberine and their impact on glycemia: a randomized, controlled, crossover pilot trial. Nutrients. 2021;14(1):124.
Stay current.
Get updates when the evidence changes. No spam, no sales.